TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2012351

Group type: EXPERIMENTAL
Intervention: Single-dose therapy with trimethoprim-sulfamethoxazole (320-1600 mg)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 10 days of therapy with trimethoprim-sulfamethoxazole (160-800 mg twice daily)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 10 days of therapy for patients with upper tract symptoms
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Single-dose therapy for patients with lower tract symptoms
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Single-dose therapy for patients less than or equal to 65 years
Number of subjects: 119

Group type: COMPARATOR
Intervention: No therapy for patients older than 65 years
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Overall resolution in younger women (less than or equal to 65 years)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Overall resolution in older women (greater than 65 years)
Number of subjects: 119
Study: 7046318

Group type: EXPERIMENTAL
Intervention: Sclerosant injection
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rubber band ligation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neither treatment
Number of subjects: 50
Study: 31907924

Group type: EXPERIMENTAL
Intervention: Minocycline 1%
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Minocycline 3%
Number of subjects: 270

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 270
Study: 30765264

Group type: EXPERIMENTAL
Intervention: Laparoscopic adhesiolysis
Number of subjects: 104

Group type: COMPARATOR
Intervention: Open adhesiolysis
Number of subjects: 104
Study: 28905189

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2) and Dexamethasone (20 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bortezomib-Dexamethasone plus Oral Cyclophosphamide (50 mg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bortezomib and Dexamethasone
Number of subjects: 96

Group type: COMPARATOR
Intervention: Bortezomib-Dexamethasone plus Oral Cyclophosphamide
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bortezomib-Dexamethasone
Number of subjects: 96
Study: 26111665

Group type: EXPERIMENTAL
Intervention: McGRATH MAC laryngoscope (McG group; 25 patients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (McL group; 25 patients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: McGRATH MAC laryngoscope (McG group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (McL group)
Number of subjects: 50
Study: 23749315

Group type: EXPERIMENTAL
Intervention: TENS (30 min, twice a week for 12 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Oxybutynin (daily slow release 10 mg for 12 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TENS + Oxybutynin (multimodal treatment for 12 weeks)
Number of subjects: 75
Study: 22282770

Group type: EXPERIMENTAL
Intervention: Supervised group exercises once a week
Number of subjects: 257
Study: 19131461

Group type: EXPERIMENTAL
Intervention: Combined measurement of fasting plasma glucose (FPG) and A1C
Number of subjects: 6736

Group type: COMPARATOR
Intervention: Fasting plasma glucose (FPG) alone
Number of subjects: 6736

Group type: COMPARATOR
Intervention: A1C alone
Number of subjects: 6736
Study: 17450704

Group type: EXPERIMENTAL
Intervention: Reporting the presence of MBD in the screening mammography results letter along with an information pamphlet
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control group (no MBD information provided)
Number of subjects: 618
Study: 15354105

Group type: EXPERIMENTAL
Intervention: MECC System (group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass (group B)
Number of subjects: 100
Study: 11773686

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary interventions (PCI) with > or =3 stents
Number of subjects: 115
Study: 10091202

Group type: EXPERIMENTAL
Intervention: Oral 17 beta‐estradiol, 2 mg/day for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 33
Study: 7808029

Group type: EXPERIMENTAL
Intervention: ATRA and intensive chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 2569486

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg) with concurrent high potency antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine (40 mg) with antacid ingested 2 hours after administration
Number of subjects: 0
Study: 76394

Group type: EXPERIMENTAL
Intervention: Beta-methasone valerate 0.1%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Beta-methasone valerate 1.0%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hydrocortisone butyrate 0.1% with plastic occlusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo creams
Number of subjects: 7
Study: 31842232

Group type: EXPERIMENTAL
Intervention: Acute care at home
Number of subjects: 91
Study: 30044291

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0% starting concentration, adjusted by 0.2% step size)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal renal function, 21 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients with ESRD
Number of subjects: 20
Study: 28396046

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS) injections
Number of subjects: 27
Study: 25791513

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA-based screening)
Number of subjects: 13515

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 13515
Study: 23736093

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 288
Study: 21221991

Group type: EXPERIMENTAL
Intervention: Taekwondo training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Operator-triggered drops
Number of subjects: 22
Study: 19217212

Group type: EXPERIMENTAL
Intervention: Unresolved trauma in abused women
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Experimental stress challenge (TSST)
Number of subjects: 44
Study: 17944785

Group type: EXPERIMENTAL
Intervention: Incredible Years (IY) Basic parent training (PT) programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (WL) control group
Number of subjects: 0
Study: 15588037

Group type: EXPERIMENTAL
Intervention: Diskus
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: pMDI
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Volumatic
Number of subjects: 15
Study: 11247619

Group type: EXPERIMENTAL
Intervention: Structured problem solving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) medication
Number of subjects: 0
Study: 9812648

Group type: EXPERIMENTAL
Intervention: Glibenclamide + Kelening
Number of subjects: 65

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 65
Study: 7963870

Group type: EXPERIMENTAL
Intervention: Elastic stockings worn for four weeks (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elastic stockings worn for four weeks (Group B)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (removal of stockings)
Number of subjects: 20
Study: 3311571

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink (isocaloric glucose)
Number of subjects: 10
Study: 31478556

Group type: EXPERIMENTAL
Intervention: 6-Fr sheath
Number of subjects: 214

Group type: COMPARATOR
Intervention: 7-Fr sheath
Number of subjects: 214
Study: 31843232

Group type: EXPERIMENTAL
Intervention: Lower serum albumin levels
Number of subjects: 3254
Study: 29602978

Group type: COMPARATOR
Intervention: Diane‐35 alone (D group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Diane‐35 plus orlistat (DO group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Diane‐35 plus metformin (DM group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Diane‐35 plus orlistat plus metformin (DOM group)
Number of subjects: 240
Study: 27825638

Group type: COMPARATOR
Intervention: Erlotinib (150 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Erlotinib plus Cabozantinib (150 mg + 40 mg)
Number of subjects: 125
Study: 25138333

Group type: EXPERIMENTAL
Intervention: Sustained care (n = 198) with automated interactive voice response telephone calls and choice of free smoking cessation medication for up to 90 days
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Sustained care (n = 198)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Standard care (n = 199)
Number of subjects: 397
Study: 23746142

Group type: EXPERIMENTAL
Intervention: cRFA followed by interferon (IFN)‐α, 9 MIU, s.c., three times per week (Study 1)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: cRFA followed by sunitinib in repeated 6‐week cycles of 50 mg/day orally for 4 weeks, then 2 weeks off treatment (Study 2)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: sunitinib alone (Study 3)
Number of subjects: 114
Study: 21943128

Group type: EXPERIMENTAL
Intervention: Developed countries
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Developing countries
Number of subjects: 28
Study: 18356205

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 114
Study: 16328419

Group type: EXPERIMENTAL
Intervention: Stellar ganglion blockade by diadynamic current in Group II
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical therapy and exercise with physical therapy agents in both groups
Number of subjects: 30
Study: 12755841

Group type: EXPERIMENTAL
Intervention: lansoprazole-clarithromycin-metronidazole
Number of subjects: 88

Group type: COMPARATOR
Intervention: lansoprazole-clarithromycin-amoxicillin
Number of subjects: 88
Study: 11219963

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 mg/70 kg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8637993

Group type: EXPERIMENTAL
Intervention: Oral CT contrast agents
Number of subjects: 30
Study: 1453208

Group type: EXPERIMENTAL
Intervention: Hickman catheter
Number of subjects: 100

Group type: COMPARATOR
Intervention: Port‐a‐Cath
Number of subjects: 100
Study: 3905061

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study: 30778858

Group type: EXPERIMENTAL
Intervention: PINQ-PHONE questionnaire
Number of subjects: 769
Study: 30829159

Group type: EXPERIMENTAL
Intervention: Supportive tools provided to 46 practices
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (42 practices without intervention)
Number of subjects: 88
Study: 26349600

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 110
Study: 25514303

Group type: EXPERIMENTAL
Intervention: High-glycemic index, high-carbohydrate diet (65% on glucose scale, 58% energy)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Low-glycemic index, high-carbohydrate diet (40%)
Number of subjects: 163

Group type: COMPARATOR
Intervention: High-glycemic index, low-carbohydrate diet (40% energy)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Low-glycemic index, low-carbohydrate diet
Number of subjects: 163
Study: 22462635

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived cells (BMCs) transplantation
Number of subjects: 27
Study: 20410089

Group type: EXPERIMENTAL
Intervention: n-3 long-chain polyunsaturated fatty acid supplementation (200 mg EPA plus 500 mg DHA)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 867
Study: 18683786

Group type: EXPERIMENTAL
Intervention: COPD group
Number of subjects: 19
Study: 16231596

Group type: EXPERIMENTAL
Intervention: Standard Treatment Group (n=5 students) received the basic module 'ADHD theory and school-based interventions' (6 h)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intensive Treatment Group (n=6 students) received the basic module plus 'Student-related training in Contingency Management' (total 14h)
Number of subjects: 11
Study: 11874767

Group type: EXPERIMENTAL
Intervention: Inoveon Diabetic Retinopathy (DR‐3DT) system
Number of subjects: 290

Group type: COMPARATOR
Intervention: Film 'gold standard'
Number of subjects: 290
Study: 10094218

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg twice daily) via Diskus
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Diskus and Diskhaler
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 213
Study: 7489431

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 2185810

Group type: EXPERIMENTAL
Intervention: Capitation system of remuneration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fee-for-service
Number of subjects: 0
Study: 24512

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg intravenously
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg orally
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (both IV and oral)
Number of subjects: 6
Study: 31770296

Group type: EXPERIMENTAL
Intervention: Pregabalin (2 mg/kg twice daily for 5 days post-surgery)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 30601819

Group type: EXPERIMENTAL
Intervention: Eccentric cycling training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Concentric cycling training
Number of subjects: 23
Study: 28771386

Group type: EXPERIMENTAL
Intervention: Parental stress at baseline (for children 16 years or older)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased child-rated parental protectiveness (for children less than 16 years old)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low parental monitoring and supervision
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parental history of conduct disorder
Number of subjects: 0
Study: 26552756

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study: 23122829

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 21592721

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nonassisted surgery
Number of subjects: 120
Study: 19386052

Group type: EXPERIMENTAL
Intervention: Interval exercise (n=14)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interval exercise (n=22)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TV watching (n=14)
Number of subjects: 36

Group type: COMPARATOR
Intervention: TV watching (n=22)
Number of subjects: 36
Study: 17351187

Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization
Number of subjects: 510

Group type: COMPARATOR
Intervention: No coronary intervention before vascular surgery
Number of subjects: 510
Study: 15203432

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for six weekly one-hour sessions
Number of subjects: 61

Group type: COMPARATOR
Intervention: Supportive Therapy (SP) for six weekly one-hour sessions
Number of subjects: 61
Study: 11246324

Group type: EXPERIMENTAL
Intervention: Protective gown and glove isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strict handwashing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gown and glove isolation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Handwashing compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gowning and gloving compliance
Number of subjects: 0
Study: 9935252

Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin orally before surgery as a single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg trovafloxacin orally before surgery as multiple doses
Number of subjects: 0
Study: 7860441

Group type: EXPERIMENTAL
Intervention: Therapeutic administration of platelet concentrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic administration of platelets
Number of subjects: 0
Study: 3354496

Group type: EXPERIMENTAL
Intervention: Calcium from milk
Number of subjects: 13

Group type: COMPARATOR
Intervention: Calcium from spinach
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Comparison of calcium absorption
Number of subjects: 13
Study: 31815770

Group type: EXPERIMENTAL
Intervention: Intravenous infusion nanotechnology monitoring system with fuzzy logic alarm algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30732142

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Radiotherapy of head and neck regions
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Socioeconomic and education status
Number of subjects: 225

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 225
Study: 28824055

Group type: EXPERIMENTAL
Intervention: Tiotropium via Respimat® with a spacer (AeroChamber®)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tiotropium via Respimat® without a spacer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 18
Study: 25355179

Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN program
Number of subjects: 779

Group type: COMPARATOR
Intervention: Healthy Teens (attention-control intervention)
Number of subjects: 779
Study: 24022375

Group type: EXPERIMENTAL
Intervention: Dementia Care Mapping (DCM)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: VIPS practice model (VPM)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control group (education of nursing home staff about dementia)
Number of subjects: 624
Study: 21706518

Group type: COMPARATOR
Intervention: 400 IU of vitamin D(3) per day
Number of subjects: 494

Group type: COMPARATOR
Intervention: 2000 IU of vitamin D(3) per day
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: 4000 IU of vitamin D(3) per day
Number of subjects: 494
Study: 19798610

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided transmural drainage (EUD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional transmural drainage (CTD)
Number of subjects: 60
Study: 16848141

Group type: EXPERIMENTAL
Intervention: Follicular phase (high conception risk phase)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Luteal phase
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: First five days of the cycle (low estrogen level)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Anthropometric facial traits
Number of subjects: 2
Study: 15370099

Group type: EXPERIMENTAL
Intervention: Kiwi fruit consumption (2 or 3 kiwi fruit per day for 28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10786740

Group type: EXPERIMENTAL
Intervention: Bupivacaine in 0.9% glucose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine in 8% glucose
Number of subjects: 60
Study: 9574235

Group type: EXPERIMENTAL
Intervention: Individually risk-adjusted follow-up programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled economic studies
Number of subjects: 0
Study: 8324023

Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg daily for 10 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: amoxicillin-clavulanic
Number of subjects: 101

Group type: COMPARATOR
Intervention: erythromycin
Number of subjects: 101
Study: 3567865

Group type: EXPERIMENTAL
Intervention: OK-432
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (transurethral resection only)
Number of subjects: 78
Study: 30333922

Group type: EXPERIMENTAL
Intervention: Personalised Performance Dashboard during monthly supervision
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard monthly supervision without the Dashboard
Number of subjects: 148
Study: 27427308

Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE) administered to 1341 residents (47% of eligible)
Number of subjects: 7682

Group type: EXPERIMENTAL
Intervention: Cognitive function assessment using MMSE
Number of subjects: 7682
Study: 25018037

Group type: EXPERIMENTAL
Intervention: Abiraterone 1000 mg plus prednisone 5 mg by mouth twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 0
Study: 24054956

Group type: EXPERIMENTAL
Intervention: Rate-control
Number of subjects: 2248

Group type: COMPARATOR
Intervention: Rhythm-control
Number of subjects: 2248
Study: 21914596

Group type: EXPERIMENTAL
Intervention: Repetitive PROM stretching
Number of subjects: 15

Group type: COMPARATOR
Intervention: Prolonged PROM stretching
Number of subjects: 15
Study: 19120893

Group type: EXPERIMENTAL
Intervention: Tailored eradication therapy (PPI/AC for CAM-sensitive strains, PPI/AM for CAM-resistant strains)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (PPI/AC therapy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Tailored eradication therapy for CAM-resistant strains
Number of subjects: 70
Study: 16634738

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy for 6 weeks
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy for 6 months
Number of subjects: 897

Group type: COMPARATOR
Intervention: Anticoagulant therapy (6 weeks or 6 months)
Number of subjects: 897
Study: 12711662

Group type: EXPERIMENTAL
Intervention: Individual counselling (3 sessions)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Group treatment (2 weeks + 4 out-patient sessions)
Number of subjects: 161
Study: 10579608

Group type: EXPERIMENTAL
Intervention: Automatic alerting system
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (no automatic notification)
Number of subjects: 192